“Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management
Immune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient’s immune system, representing a major breakthrough in the field of cancer therapy. Monoclonal antibodies including anti-cytotoxic T-lymphocyte–associated prot...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-05-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2021.1889449 |
| _version_ | 1797674558210179072 |
|---|---|
| author | Pietro Sollena Simone Cappilli Francesco Federico Giovanni Schinzari Giampaolo Tortora Ketty Peris |
| author_facet | Pietro Sollena Simone Cappilli Francesco Federico Giovanni Schinzari Giampaolo Tortora Ketty Peris |
| author_sort | Pietro Sollena |
| collection | DOAJ |
| description | Immune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient’s immune system, representing a major breakthrough in the field of cancer therapy. Monoclonal antibodies including anti-cytotoxic T-lymphocyte–associated protein 4, anti–programmed cell death protein 1 and its ligand inhibitors have been approved for advanced melanoma among other solid cancers. Although immunotherapy demonstrated a good safety profile, a new spectrum of multisystemic immune-related adverse events has been recently reported due to their use. Cutaneous reactions represent one of the leading adverse events, often reported in literature as “skin rash”, and rarely further characterized in distinct dermatologic entities. Herein we describe the distinctive cutaneous rashes occurring during immunotherapies for advanced melanoma, discussing implications in the treatment management. |
| first_indexed | 2024-03-11T22:00:45Z |
| format | Article |
| id | doaj.art-8ce116d87df643c8864405b50ad086c1 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:00:45Z |
| publishDate | 2022-05-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-8ce116d87df643c8864405b50ad086c12023-09-25T11:13:19ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-05-0118310.1080/21645515.2021.18894491889449“Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic managementPietro Sollena0Simone Cappilli1Francesco Federico2Giovanni Schinzari3Giampaolo Tortora4Ketty Peris5Fondazione Policlinico Universitario A. Gemelli IRCCSUniversità Cattolica del Sacro CuoreFondazione Policlinico Universitario A. Gemelli IRCCSFondazione Policlinico Universitario A. Gemelli IRCCSFondazione Policlinico Universitario A. Gemelli IRCCSFondazione Policlinico Universitario A. Gemelli IRCCSImmune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient’s immune system, representing a major breakthrough in the field of cancer therapy. Monoclonal antibodies including anti-cytotoxic T-lymphocyte–associated protein 4, anti–programmed cell death protein 1 and its ligand inhibitors have been approved for advanced melanoma among other solid cancers. Although immunotherapy demonstrated a good safety profile, a new spectrum of multisystemic immune-related adverse events has been recently reported due to their use. Cutaneous reactions represent one of the leading adverse events, often reported in literature as “skin rash”, and rarely further characterized in distinct dermatologic entities. Herein we describe the distinctive cutaneous rashes occurring during immunotherapies for advanced melanoma, discussing implications in the treatment management.http://dx.doi.org/10.1080/21645515.2021.1889449advanced melanomacutaneous adverse eventsimmune checkpoint inhibitorspd-1 inhibitorsctla-4 inhibitorsskin rash |
| spellingShingle | Pietro Sollena Simone Cappilli Francesco Federico Giovanni Schinzari Giampaolo Tortora Ketty Peris “Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management Human Vaccines & Immunotherapeutics advanced melanoma cutaneous adverse events immune checkpoint inhibitors pd-1 inhibitors ctla-4 inhibitors skin rash |
| title | “Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management |
| title_full | “Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management |
| title_fullStr | “Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management |
| title_full_unstemmed | “Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management |
| title_short | “Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management |
| title_sort | skin rashes and immunotherapy in melanoma distinct dermatologic adverse events and implications for therapeutic management |
| topic | advanced melanoma cutaneous adverse events immune checkpoint inhibitors pd-1 inhibitors ctla-4 inhibitors skin rash |
| url | http://dx.doi.org/10.1080/21645515.2021.1889449 |
| work_keys_str_mv | AT pietrosollena skinrashesandimmunotherapyinmelanomadistinctdermatologicadverseeventsandimplicationsfortherapeuticmanagement AT simonecappilli skinrashesandimmunotherapyinmelanomadistinctdermatologicadverseeventsandimplicationsfortherapeuticmanagement AT francescofederico skinrashesandimmunotherapyinmelanomadistinctdermatologicadverseeventsandimplicationsfortherapeuticmanagement AT giovannischinzari skinrashesandimmunotherapyinmelanomadistinctdermatologicadverseeventsandimplicationsfortherapeuticmanagement AT giampaolotortora skinrashesandimmunotherapyinmelanomadistinctdermatologicadverseeventsandimplicationsfortherapeuticmanagement AT kettyperis skinrashesandimmunotherapyinmelanomadistinctdermatologicadverseeventsandimplicationsfortherapeuticmanagement |